


# SARS-CoV-2 infection weakens immune-cell response to vaccination, suggests study

March 20 2023



Graphical Abstract. Credit: *Immunity* (2023). DOI: 10.1016/j.immuni.2023.03.005

The magnitude and quality of a key immune cell's response to vaccination with two doses of the Pfizer-BioNTech COVID-19 vaccine were considerably lower in people with prior SARS-CoV-2 infection compared to people without prior infection, a study has found.

In addition, the level of this key immune cell that targets the SARS-CoV-2 spike protein was substantially lower in unvaccinated people with COVID-19 than in vaccinated people who had never been infected. Importantly, people who recover from SARS-CoV-2 infection and then get vaccinated are more protected than people who are unvaccinated. These findings, which suggest that the virus damages an important immune-cell response, were published today in the journal *Immunity*.

The study was led by Mark M. Davis, Ph.D. Dr. Davis is the director of the Stanford Institute for Immunity, Transplantation and Infection and a professor of microbiology and immunology at Stanford University School of Medicine in Palo Alto, California. He is also a Howard Hughes Medical Institute Investigator.

Dr. Davis and colleagues designed a very sensitive tool to analyze how immune cells called CD4+ T cells and CD8+ T cells respond to SARS-CoV-2 infection and vaccination. These cells coordinate the [immune system](#)'s response to the virus and kill other cells that have been infected, helping prevent COVID-19.

The tool was designed to identify T cells that target any of dozens of specific regions on the virus's spike protein as well as some other viral regions. The Pfizer-BioNTech vaccine uses parts of the SARS-CoV-2

spike protein to elicit an [immune response](#) without causing infection.

The investigators studied CD4+ and CD8+ T-cell responses in [blood samples](#) from three groups of volunteers. One group had never been infected with SARS-CoV-2 and received two doses of the Pfizer-BioNTech COVID-19 vaccine. The second group had previously been infected with SARS-CoV-2 and received two doses of the vaccine. The third group had COVID-19 and was unvaccinated.

The researchers found that vaccination of people who had never been infected with SARS-CoV-2 induced robust CD4+ and CD8+ T-cell responses to the virus' spike protein. In addition, these T cells produced multiple types of cell-signaling molecules called cytokines, which recruit other [immune cells](#)—including antibody-producing B cells—to fight pathogens.

However, people who had been infected with SARS-CoV-2 prior to vaccination produced spike-specific CD8+ T cells at considerably lower levels—and with less functionality—than vaccinated people who had never been infected. Moreover, the researchers observed substantially lower levels of spike-specific CD8+ T cells in unvaccinated people with COVID-19 than in vaccinated people who had never been infected.

Taken together, the investigators write, these findings suggest that SARS-CoV-2 infection damages the CD8+ T cell response, an effect akin to that observed in earlier studies showing long-term damage to the immune system after [infection](#) with viruses such as hepatitis C or HIV. The new findings highlight the need to develop vaccination strategies to specifically boost antiviral CD8+ T cell responses in people previously infected with SARS-CoV-2, the researchers conclude.

**More information:** Fei Gao et al, Robust T cell responses to Pfizer/BioNTech vaccine compared to infection and evidence of

attenuated peripheral CD8+ T cell responses due to COVID-19,  
*Immunity* (2023). [DOI: 10.1016/j.immuni.2023.03.005](https://doi.org/10.1016/j.immuni.2023.03.005)

Provided by National Institutes of Health

Citation: SARS-CoV-2 infection weakens immune-cell response to vaccination, suggests study (2023, March 20) retrieved 8 May 2024 from <https://medicalxpress.com/news/2023-03-sars-cov-infection-weakens-immune-cell-response.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.